Humana (NYSE:HUM)‘s stock had its “buy” rating reaffirmed by equities research analysts at Mizuho in a report released on Friday, TipRanks reports. They currently have a $405.00 price objective on the insurance provider’s stock. Mizuho’s target price indicates a potential upside of 7.76% from the stock’s current price.
HUM has been the subject of several other research reports. UBS Group boosted their price target on Humana from $321.00 to $406.00 and gave the company a “neutral” rating in a research note on Thursday, January 23rd. Credit Suisse Group boosted their price target on Humana from $378.00 to $400.00 and gave the company an “outperform” rating in a research note on Wednesday, January 8th. JPMorgan Chase & Co. boosted their price target on Humana from $437.00 to $448.00 and gave the company an “overweight” rating in a research note on Friday, January 3rd. Cantor Fitzgerald upped their target price on Humana from $345.00 to $400.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 5th. Finally, Wells Fargo & Co reaffirmed an “overweight” rating and set a $400.00 target price (up previously from $338.00) on shares of Humana in a research report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and thirteen have given a buy rating to the company’s stock. Humana has an average rating of “Buy” and a consensus target price of $380.50.
Shares of NYSE HUM opened at $375.85 on Friday. The stock has a market cap of $46.75 billion, a price-to-earnings ratio of 18.72, a PEG ratio of 1.41 and a beta of 0.95. The business has a 50 day simple moving average of $360.28 and a 200 day simple moving average of $316.11. Humana has a 52 week low of $225.65 and a 52 week high of $381.04. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.83 and a current ratio of 1.82.
Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, February 5th. The insurance provider reported $2.28 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.20 by $0.08. The business had revenue of $16.30 billion during the quarter, compared to analysts’ expectations of $16.15 billion. Humana had a return on equity of 20.89% and a net margin of 4.17%. The firm’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.65 EPS. On average, analysts predict that Humana will post 18.65 EPS for the current year.
In other news, insider Elizabeth D. Bierbower sold 5,347 shares of the stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $370.00, for a total value of $1,978,390.00. Following the completion of the sale, the insider now directly owns 23,439 shares of the company’s stock, valued at $8,672,430. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James J. /Ky Obrien sold 2,500 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $345.21, for a total value of $863,025.00. Insiders have sold 45,294 shares of company stock valued at $15,894,412 in the last ninety days. Company insiders own 0.54% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Endurance Wealth Management Inc. boosted its position in shares of Humana by 354.5% in the third quarter. Endurance Wealth Management Inc. now owns 100 shares of the insurance provider’s stock valued at $26,000 after acquiring an additional 78 shares during the period. Evoke Wealth LLC bought a new stake in shares of Humana in the third quarter valued at approximately $26,000. Quest Capital Management Inc. ADV bought a new stake in shares of Humana in the third quarter valued at approximately $30,000. Penserra Capital Management LLC bought a new stake in shares of Humana in the third quarter valued at approximately $31,000. Finally, Lighthouse Financial Advisors Inc. bought a new stake in shares of Humana in the fourth quarter valued at approximately $31,000. 94.44% of the stock is owned by institutional investors.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Article: What is Cost of Debt?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.